These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 30897988)
1. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Cervantes CE; Merino JL; Barrios V Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):319-330. PubMed ID: 30897988 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971 [TBL] [Abstract][Full Text] [Related]
4. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434 [TBL] [Abstract][Full Text] [Related]
5. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Link MS; Giugliano RP; Ruff CT; Scirica BM; Huikuri H; Oto A; Crompton AE; Murphy SA; Lanz H; Mercuri MF; Antman EM; Braunwald E; Circ Arrhythm Electrophysiol; 2017 Jan; 10(1):. PubMed ID: 28077507 [TBL] [Abstract][Full Text] [Related]
6. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. Steffel J; Giugliano RP; Braunwald E; Murphy SA; Mercuri M; Choi Y; Aylward P; White H; Zamorano JL; Antman EM; Ruff CT J Am Coll Cardiol; 2016 Sep; 68(11):1169-1178. PubMed ID: 27609678 [TBL] [Abstract][Full Text] [Related]
7. Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Dzeshka MS; Lip GY Expert Opin Pharmacother; 2015; 16(17):2661-78. PubMed ID: 26559069 [TBL] [Abstract][Full Text] [Related]
8. Edoxaban: a review in nonvalvular atrial fibrillation. McCormack PL Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340 [TBL] [Abstract][Full Text] [Related]
9. Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. Zimerman A; Braunwald E; Steffel J; Van Mieghem NM; Palazzolo MG; Murphy SA; Chen CZL; Unverdorben M; Ruff CT; Antman EM; Giugliano RP JAMA Cardiol; 2024 Sep; 9(9):817-825. PubMed ID: 38985461 [TBL] [Abstract][Full Text] [Related]
10. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289 [TBL] [Abstract][Full Text] [Related]
11. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288 [TBL] [Abstract][Full Text] [Related]
12. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial. Fanola CL; Ruff CT; Murphy SA; Jin J; Duggal A; Babilonia NA; Sritara P; Mercuri MF; Kamphuisen PW; Antman EM; Braunwald E; Giugliano RP J Am Heart Assoc; 2018 Aug; 7(16):e008987. PubMed ID: 30369307 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Chao TF; Chen SA; Ruff CT; Hamershock RA; Mercuri MF; Antman EM; Braunwald E; Giugliano RP Eur Heart J; 2019 May; 40(19):1518-1527. PubMed ID: 30590425 [TBL] [Abstract][Full Text] [Related]
15. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study). Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605 [TBL] [Abstract][Full Text] [Related]
16. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY; Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218 [TBL] [Abstract][Full Text] [Related]
17. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556 [TBL] [Abstract][Full Text] [Related]
19. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226 [TBL] [Abstract][Full Text] [Related]
20. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Rutman H; Mercuri MF; Antman EM; Braunwald E; Giugliano RP Eur Heart J; 2019 May; 40(19):1541-1550. PubMed ID: 30624719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]